Heightened	O
HIV	B:C0019683
antibody	I:C0019683
responses	O
in	O
postpartum	O
women	O
as	O
exemplified	O
by	O
recent	O
infection	O
assays	I:C0005507
:	O
implications	O
for	O
incidence	O
estimates	O
.	O

Heightened	O
HIV	O
antibody	I:C0019683
responses	B:C0003261
in	O
postpartum	O
women	O
as	O
exemplified	O
by	O
recent	O
infection	O
assays	I:C0005507
:	O
implications	O
for	O
incidence	O
estimates	O
.	O

Heightened	O
HIV	O
antibody	I:C0019683
responses	O
in	O
postpartum	O
women	O
as	O
exemplified	O
by	O
recent	O
infection	B:C0005507
assays	I:C0005507
:	O
implications	O
for	O
incidence	O
estimates	O
.	O

Laboratory	B:C0005507
assays	I:C0005507
that	O
identify	O
recent	O
HIV	I:C0019693
infections	I:C0019693
are	O
important	O
for	O
assessing	O
impacts	O
of	O
interventions	O
aimed	O
at	O
reducing	O
HIV	O
incidence	O
.	O

Laboratory	O
assays	I:C0005507
that	O
identify	O
recent	B:C0019693
HIV	I:C0019693
infections	I:C0019693
are	O
important	O
for	O
assessing	O
impacts	O
of	O
interventions	O
aimed	O
at	O
reducing	O
HIV	O
incidence	O
.	O

Laboratory	O
assays	I:C0005507
that	O
identify	O
recent	O
HIV	I:C0019693
infections	I:C0019693
are	O
important	O
for	O
assessing	O
impacts	O
of	O
interventions	B:C1273869
aimed	O
at	O
reducing	O
HIV	O
incidence	O
.	O

Laboratory	O
assays	I:C0005507
that	O
identify	O
recent	O
HIV	I:C0019693
infections	I:C0019693
are	O
important	O
for	O
assessing	O
impacts	O
of	O
interventions	O
aimed	O
at	O
reducing	O
HIV	B:C0019693
incidence	O
.	O

Kinetics	O
of	O
HIV	B:C0019693
humoral	O
responses	I:C1155229
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	O
subtypes	O
,	O
populations	O
and	O
physiological	O
states	I:C0031843
.	O

Kinetics	O
of	O
HIV	O
humoral	B:C1155229
responses	I:C1155229
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	O
subtypes	O
,	O
populations	O
and	O
physiological	O
states	I:C0031843
.	O

Kinetics	O
of	O
HIV	O
humoral	O
responses	I:C1155229
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	B:C0019682
subtypes	O
,	O
populations	O
and	O
physiological	O
states	I:C0031843
.	O

Kinetics	O
of	O
HIV	O
humoral	O
responses	I:C1155229
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	O
subtypes	B:C0449560
,	O
populations	O
and	O
physiological	O
states	I:C0031843
.	O

Kinetics	O
of	O
HIV	O
humoral	O
responses	I:C1155229
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	O
subtypes	O
,	O
populations	B:C1257890
and	O
physiological	O
states	I:C0031843
.	O

Kinetics	O
of	O
HIV	O
humoral	O
responses	I:C1155229
can	O
vary	O
with	O
inherent	O
assay	O
properties	O
,	O
and	O
between	O
HIV	O
subtypes	O
,	O
populations	O
and	O
physiological	B:C0031843
states	I:C0031843
.	O

They	O
are	O
important	O
in	O
determining	O
mean	O
duration	O
of	O
recent	O
infection	O
(	O
MDRI	O
)	O
for	O
antibody	B:C0005507
-	I:C0005507
based	I:C0005507
assays	I:C0005507
for	O
detecting	O
recent	O
HIV	I:C0019693
infections	I:C0019693
.	O

They	O
are	O
important	O
in	O
determining	O
mean	O
duration	O
of	O
recent	O
infection	O
(	O
MDRI	O
)	O
for	O
antibody	O
-	I:C0005507
based	I:C0005507
assays	I:C0005507
for	O
detecting	B:C1511790
recent	O
HIV	I:C0019693
infections	I:C0019693
.	O

They	O
are	O
important	O
in	O
determining	O
mean	O
duration	O
of	O
recent	O
infection	O
(	O
MDRI	O
)	O
for	O
antibody	O
-	I:C0005507
based	I:C0005507
assays	I:C0005507
for	O
detecting	O
recent	B:C0019693
HIV	I:C0019693
infections	I:C0019693
.	O

We	O
determined	O
MDRIs	O
for	O
BED	B:C0086231
-	I:C0086231
CEIA	I:C0086231
,	O
LAg	O
and	O
BRAI	O
assays	I:C0086231
for	O
101	O
seroconverting	O
postpartum	O
women	O
,	O
recruited	O
in	O
Harare	O
in	O
1997	O
-	O
2000	O
during	O
the	O
Zimbabwe	O
Vitamin	I:C0008976
A	I:C0008976
for	I:C0008976
Mothers	I:C0008976
and	I:C0008976
Babies	I:C0008976
(	I:C0008976
ZVITAMBO	I:C0008976
)	I:C0008976

We	O
determined	O
MDRIs	O
for	O
BED	O
-	I:C0086231
CEIA	I:C0086231
,	O
LAg	B:C0086231
and	O
BRAI	O
assays	I:C0086231
for	O
101	O
seroconverting	O
postpartum	O
women	O
,	O
recruited	O
in	O
Harare	O
in	O
1997	O
-	O
2000	O
during	O
the	O
Zimbabwe	O
Vitamin	I:C0008976
A	I:C0008976
for	I:C0008976
Mothers	I:C0008976
and	I:C0008976
Babies	I:C0008976
(	I:C0008976
ZVITAMBO	I:C0008976
)	I:C0008976

We	O
determined	O
MDRIs	O
for	O
BED	O
-	I:C0086231
CEIA	I:C0086231
,	O
LAg	O
and	O
BRAI	B:C0086231
assays	I:C0086231
for	O
101	O
seroconverting	O
postpartum	O
women	O
,	O
recruited	O
in	O
Harare	O
in	O
1997	O
-	O
2000	O
during	O
the	O
Zimbabwe	O
Vitamin	I:C0008976
A	I:C0008976
for	I:C0008976
Mothers	I:C0008976
and	I:C0008976
Babies	I:C0008976
(	I:C0008976
ZVITAMBO	I:C0008976
)	I:C0008976

We	O
determined	O
MDRIs	O
for	O
BED	O
-	I:C0086231
CEIA	I:C0086231
,	O
LAg	O
and	O
BRAI	O
assays	I:C0086231
for	O
101	O
seroconverting	O
postpartum	O
women	O
,	O
recruited	O
in	O
Harare	O
in	O
1997	O
-	O
2000	O
during	O
the	O
Zimbabwe	B:C0008976
Vitamin	I:C0008976
A	I:C0008976
for	I:C0008976
Mothers	I:C0008976
and	I:C0008976
Babies	I:C0008976
(	I:C0008976
ZVITAMBO	I:C0008976
)	I:C0008976

Trial	I:C0008976
,	O
comparing	O
them	O
against	O
published	B:C0993637
MDRIs	O
estimated	O
from	O
seroconverting	O
cases	O
in	O
the	O
general	O
population	I:C0683971
.	O

Trial	I:C0008976
,	O
comparing	O
them	O
against	O
published	O
MDRIs	O
estimated	O
from	O
seroconverting	O
cases	O
in	O
the	O
general	B:C0683971
population	I:C0683971
.	O

We	O
also	O
compared	O
MDRIs	O
for	O
women	B:C0043210
who	O
seroconverted	O
either	O
during	O
the	O
first	O
nine	O
months	O
,	O
or	O
at	O
later	O
stages	O
,	O
postpartum	O
.	O

At	O
cut	O
-	O
offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	B:C0086231
,	O
1.5	O
for	O
LAg	O
and	O
40	O
%	O
for	O
BRAI	O
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32	O
-	O
41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	O
estimates	I:C0993637
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	O
C	I:C0449560
samples	O
from	O
general	O
populations	I:C0683971
.	O

At	O
cut	O
-	O
offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	O
,	O
1.5	O
for	O
LAg	B:C0086231
and	O
40	O
%	O
for	O
BRAI	O
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32	O
-	O
41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	O
estimates	I:C0993637
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	O
C	I:C0449560
samples	O
from	O
general	O
populations	I:C0683971
.	O

At	O
cut	O
-	O
offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	O
,	O
1.5	O
for	O
LAg	O
and	O
40	O
%	O
for	O
BRAI	B:C0086231
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32	O
-	O
41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	O
estimates	I:C0993637
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	O
C	I:C0449560
samples	O
from	O
general	O
populations	I:C0683971
.	O

At	O
cut	O
-	O
offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	O
,	O
1.5	O
for	O
LAg	O
and	O
40	O
%	O
for	O
BRAI	O
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32	O
-	O
41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	B:C0993637
estimates	I:C0993637
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	O
C	I:C0449560
samples	O
from	O
general	O
populations	I:C0683971
.	O

At	O
cut	O
-	O
offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	O
,	O
1.5	O
for	O
LAg	O
and	O
40	O
%	O
for	O
BRAI	O
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32	O
-	O
41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	O
estimates	I:C0993637
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	B:C0449560
C	I:C0449560
samples	O
from	O
general	O
populations	I:C0683971
.	O

At	O
cut	O
-	O
offs	O
(	O
C	O
)	O
of	O
0.8	O
for	O
BED	O
,	O
1.5	O
for	O
LAg	O
and	O
40	O
%	O
for	O
BRAI	O
,	O
estimated	O
MDRIs	O
for	O
postpartum	O
mothers	O
,	O
were	O
192	O
,	O
104	O
and	O
144	O
days	O
,	O
33	O
%	O
,	O
32	O
-	O
41	O
%	O
and	O
52	O
%	O
lower	O
than	O
published	O
estimates	I:C0993637
of	O
287	O
,	O
152-177	O
and	O
298	O
days	O
,	O
respectively	O
,	O
for	O
clade	O
C	I:C0449560
samples	O
from	O
general	B:C0683971
populations	I:C0683971
.	O

Point	B:C1709586
estimates	I:C1709586
of	O
MDRI	O
values	O
were	O
7	O
-	O
19	O
%	O
shorter	O
for	O
women	O
who	O
seroconverted	O
in	O
the	O
first	O
9	O
-	O
months	O
postpartum	O
,	O
compared	O
with	O
those	O
seroconverting	O
later	O
.	O

Point	O
estimates	I:C1709586
of	O
MDRI	O
values	B:C1285164
were	O
7	O
-	O
19	O
%	O
shorter	O
for	O
women	O
who	O
seroconverted	O
in	O
the	O
first	O
9	O
-	O
months	O
postpartum	O
,	O
compared	O
with	O
those	O
seroconverting	O
later	O
.	O

Point	O
estimates	I:C1709586
of	O
MDRI	O
values	O
were	O
7	O
-	O
19	O
%	O
shorter	O
for	O
women	B:C0043210
who	O
seroconverted	O
in	O
the	O
first	O
9	O
-	O
months	O
postpartum	O
,	O
compared	O
with	O
those	O
seroconverting	O
later	O
.	O

MDRI	O
values	B:C1285164
for	O
three	O
HIV	O
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	O
population	I:C0683971
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	I:C1512670
soon	O
after	O
birth	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	B:C0019693
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	O
population	I:C0683971
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	I:C1512670
soon	O
after	O
birth	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	O
incidence	O
biomarkers	B:C0005516
are	O
longer	O
in	O
the	O
general	O
population	I:C0683971
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	I:C1512670
soon	O
after	O
birth	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	O
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	B:C0683971
population	I:C0683971
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	I:C1512670
soon	O
after	O
birth	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	O
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	O
population	I:C0683971
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	B:C0005615
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	I:C1512670
soon	O
after	O
birth	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	O
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	O
population	I:C0683971
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	B:C1512670
activation	I:C1512670
soon	O
after	O
birth	O
.	O

MDRI	O
values	O
for	O
three	O
HIV	O
incidence	O
biomarkers	O
are	O
longer	O
in	O
the	O
general	O
population	I:C0683971
than	O
among	O
postpartum	O
women	O
,	O
particularly	O
those	O
who	O
recently	O
gave	O
birth	O
,	O
consistent	O
with	O
heightened	O
immunologic	O
activation	I:C1512670
soon	O
after	O
birth	B:C0005615
.	O

Our	O
results	O
provide	O
a	O
caution	O
that	O
MDRI	O
may	O
vary	O
significantly	O
between	O
subjects	B:C2349001
in	O
different	O
physiological	O
states	I:C0031843
.	O

Our	O
results	O
provide	O
a	O
caution	O
that	O
MDRI	O
may	O
vary	O
significantly	O
between	O
subjects	O
in	O
different	O
physiological	B:C0031843
states	I:C0031843
.	O

